OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP) announced that the Company’s abstract illustrating research on its novel therapeutic cancer vaccine, has been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C. OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP) could very well storm Wall Street with its prostate cancer vaccine trials. The company has been making great strides in finding a cure for prostate cancer. Last month, OBMP announced that In the ongoing Phase 1 clinical trial, ProscaVax is being evaluated for safety and efficacy in prostate specific antigen (PSA) recurrent prostate cancer in hormone-naïve and hormone-independent patients. Per protocol, 20 patients are expected to be enrolled in the 1a portion of the study, with therapy consisting of six ProscaVax induction vaccinations at a single dose. To date, 16 prostate cancer patients have enrolled in the trial.
Let’s take a quick look at the technical chart for OBMP.
[intr_chart ticker=OBMP src=”https://www.journaltranscript.com/wp-content/uploads/2017/02/12581-OBMP5.png”]
The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend. However, more positive data could very well grab the eyes of big boys on WallStreet leading to a buying frenzy.